Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes.

@article{Fagerberg1995TumorRI,
  title={Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes.},
  author={Jan Fagerberg and A-K. Hjelm and Peter Ragnhammar and J E Fr{\"o}din and H Wigzell and H Mellstedt},
  journal={Cancer research},
  year={1995},
  volume={55 9},
  pages={1824-7}
}
Treatment of cancer patients with unconjugated mAbs directed against tumor-associated antigens is considered passive immunotherapy due to the main suggested effector mechanisms: antibody-dependent cellular cytotoxicity, complement-dependent cytolysis, and apoptosis. The therapeutic antibody (ab1) may, however, also give rise to an idiotypic network response, i.e., an immunizing effect. Induced anti-idiotypic antibodies (ab2) mimicking the epitope that ab1 recognizes might subsequently induce an… CONTINUE READING